pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›MIFEPRISTONE
drug
save

MIFEPRISTONE

Marketedupdated 6mo ago
by $CORT CORCEPT THERAPEUTICS INC
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval44 co-mentions · 22 sources
  • tagSmall Molecule22 co-mentions · 22 sources
  • companyEvita Solutions LLC1 co-mentions · 1 sources

all catalysts(6)

approval · 6
Apr 11, 2019
approval
8y ago
MIFEPRISTONE — FDA approval
MIFEPRISTONE
→
May 14, 2021
approval
6y ago
MIFEPRISTONE — FDA approval
MIFEPRISTONE
→
Jan 3, 2023
approval
4y ago
MIFEPRISTONE — FDA approval
MIFEPRISTONE
→
Mar 23, 2023
approval
4y ago
MIFEPRISTONE — FDA approval
MIFEPRISTONE
→
Sep 30, 2025
approval
1y ago
MIFEPRISTONE — FDA approval
MIFEPRISTONE
→
Sep 30, 2025
approval
1y ago
MIFEPRISTONE — FDA approval
MIFEPRISTONE
→

Trials studying MIFEPRISTONE

  • phase2A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancerrecruitingn=201
  • —Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortionterminatedn=129
  • phase4Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)completedn=1,113
  • phase2RESET-medication Glucocorticoid Receptor (GR) Blockade As Disease Modifying Treatment for Depression with Childhood Traumacompletedn=158
  • phase2REVERSE: Improving Treatment-resistant Post Traumatic Stress Disorder (PTSD) with Glucocorticoid Receptor (GR) Antagonismrecruitingn=60
  • phase2Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiencyterminatedn=3

Patent cliff

source: FDA Orange Book
first barrier falls
Aug 27, 2028
~1.8 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (18)

  • Aug 22, 2038method-of-use (U-1643)US 10231983
  • Aug 22, 2038method-of-use (U-1643)US 10314850
  • Aug 22, 2038method-of-use (U-1643)US 10780097
  • Jun 19, 2037method-of-use (U-1643)US 10195214
  • Jun 19, 2037method-of-use (U-1643)US 10842800
  • Jun 19, 2037method-of-use (U-1643)US 11969435
  • Jun 19, 2037method-of-use (U-1643)US 12097210
  • Jan 18, 2037method-of-use (U-1643)US 10151763
  • Aug 15, 2036method-of-use (U-1643)US 9829495
  • Aug 12, 2036method-of-use (U-1643)US 10006924
  • Aug 12, 2036method-of-use (U-1643)US 10495650
  • Apr 20, 2036method-of-use (U-1643)US 10166242
  • Apr 20, 2036method-of-use (U-1643)US 10166243
  • Apr 20, 2036method-of-use (U-1643)US 10660904
  • Apr 20, 2036method-of-use (U-1643)US 9943526
  • Mar 5, 2033method-of-use (U-1643)US 10500216
  • Nov 15, 2032method-of-use (U-1643)US 10842801
  • Aug 27, 2028method-of-use (U-1643)US 89213481.8y

News(10)

  • White House pulls nomination for FDA nominee Overton
    The sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say.
    biopharma_dive · 22h ago
  • Heidi Overton’s FDA nomination pulled by White House
    The White House is pulling Heidi Overton’s nomination to lead the FDA just hours before the Senate was scheduled to vote on her confirmation.
    fiercebiotech · 1d ago
  • FDA finalizes cell and gene therapy potency guidance
    In a final guidance issued on Monday, the US Food and Drug Administration (FDA) laid out its expectations for cell and gene therapy (CGT) sponsors to demonstrate that their products meet potency st…
    raps · 17d ago
  • Mifepristone study highlights need for more transparency, data collection in FDA’s REMS program
    Patients who reviewed and signed a patient agreement form (PAF) for mifepristone and misoprostol under the US Food and Drug Administration’s (FDA) risk evaluation and mitigation strategy (REMS) pro…
    raps · 17d ago
  • How these census changes could threaten public health
    The Trump administration wants to make three big changes to the U.S. Census, including eliminating questions about race, ethnicity, and sexual orientation and excluding anyone who is not a citizen…
    stat · 1mo ago
  • FDA says its safety review of abortion pill will continue into next year
    The FDA says its ongoing safety review of the nation's main abortion pill will continue into next year, a timeline that was quickly condemned by abortion opponents.
    stat · 1mo ago
  • Trump uses ‘contested’ power to cut more funding to HHS
    Late Friday night, the Trump administration clawed back nearly $1 billion in spending approved by Congress, targeting several HHS programs focused on immigrants and diversity
    stat · 1mo ago
  • Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug
    “With this latest appointment, mifepristone has a new boss but an old problem,” writes Julie F. Kay, founder and CEO of Reproductive Futures.
    stat · 1mo ago
  • STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and more
    President Trump’s nominee to lead the FDA was grilled by senators on hot button topics like China, vaccines, and abortion access
    stat · 1mo ago
  • Federal judge rolls back landmark disability protections
    The Justice Department said in June that it would no longer enforce laws that prioritized people with disabilities living and receiving services in their communities, rather than in nursing homes…
    stat · 1mo ago
view all news mentions →
brand
MIFEPRISTONE
generic
MIFEPRISTONE
indication
Cushing's Syndrome
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?